These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 7406113)

  • 1. Limitations of the complement-fixation test for distinguishing naturally acquired from vaccine-induced yellow fever infection in flavivirus-hyperendemic areas.
    Monath TP; Craven RB; Muth DJ; Trautt CJ; Calisher CH; Fitzgerald SA
    Am J Trop Med Hyg; 1980 Jul; 29(4):624-34. PubMed ID: 7406113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yellow fever in the Gambia, 1978--1979: epidemiologic aspects with observations on the occurrence of orungo virus infections.
    Monath TP; Craven RB; Adjukiewicz A; Germain M; Francy DB; Ferrara L; Samba EM; N'Jie H; Cham K; Fitzgerald SA; Crippen PH; Simpson DI; Bowen ET; Fabiyi A; Salaun JJ
    Am J Trop Med Hyg; 1980 Sep; 29(5):912-28. PubMed ID: 7435793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 1970 yellow fever epidemic in Okwoga District, Benue Plateau State, Nigeria. 3. Serological responses in persons with and without pre-existing heterologous group B immunity.
    Monath TP; Wilson DC; Casals J
    Bull World Health Organ; 1973; 49(3):235-44. PubMed ID: 4546521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect fluorescent antibody test for the diagnosis of yellow fever.
    Monath TP; Cropp CB; Muth DJ; Calisher CH
    Trans R Soc Trop Med Hyg; 1981; 75(2):282-6. PubMed ID: 7029803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine.
    Mason RA; Tauraso NM; Spertzel RO; Ginn RK
    Appl Microbiol; 1973 Apr; 25(4):539-44. PubMed ID: 4633476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein.
    Schlesinger JJ; Brandriss MW; Monath TP
    Virology; 1983 Feb; 125(1):8-17. PubMed ID: 6187129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48.
    Schlesinger JJ; Brandriss MW; Walsh EE
    J Immunol; 1985 Oct; 135(4):2805-9. PubMed ID: 4031501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection.
    Reinhardt B; Jaspert R; Niedrig M; Kostner C; L'age-Stehr J
    J Med Virol; 1998 Oct; 56(2):159-67. PubMed ID: 9746073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
    Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
    J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yellow fever haemagglutination-inhibiting, neutralising and IgM antibodies in vaccinated and unvaccinated residents of Ibadan, Nigeria.
    Omilabu SA; Adejumo JO; Olaleye OD; Fagbami AH; Baba SS
    Comp Immunol Microbiol Infect Dis; 1990; 13(2):95-100. PubMed ID: 2208973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sero-prevalence of yellow fever and related Flavi viruses in Ethiopia: a public health perspective.
    Mengesha Tsegaye M; Beyene B; Ayele W; Abebe A; Tareke I; Sall A; Yactayo S; Shibeshi ME; Staples E; Belay D; Lilay A; Alemu A; Alemu E; Kume A; H/Mariam A; Ronveaux O; Tefera M; Kassa W; Bekele Weyessa A; Jima D; Kebede A; Tayachew A
    BMC Public Health; 2018 Aug; 18(1):1011. PubMed ID: 30107830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.
    Poland JD; Calisher CH; Monath TP; Downs WG; Murphy K
    Bull World Health Organ; 1981; 59(6):895-900. PubMed ID: 6978196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine.
    Kayser M; Klein H; Paasch I; Pilaski J; Blenk H; Heeg K
    J Med Virol; 1985 Sep; 17(1):35-45. PubMed ID: 2995571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
    Muyanja E; Ssemaganda A; Ngauv P; Cubas R; Perrin H; Srinivasan D; Canderan G; Lawson B; Kopycinski J; Graham AS; Rowe DK; Smith MJ; Isern S; Michael S; Silvestri G; Vanderford TH; Castro E; Pantaleo G; Singer J; Gillmour J; Kiwanuka N; Nanvubya A; Schmidt C; Birungi J; Cox J; Haddad EK; Kaleebu P; Fast P; Sekaly RP; Trautmann L; Gaucher D
    J Clin Invest; 2014 Jul; 124(7):3147-58. PubMed ID: 24911151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil.
    Gonçalves AP; Almeida LT; Rezende IMd; Fradico JRB; Pereira LS; Ramalho DB; Pascoal Xavier MA; Calzavara Silva CE; Monath TP; LaBeaud AD; Drumond BP; Campi-Azevedo AC; Martins-Filho OA; Teixeira-Carvalho A; Alves PA;
    Microbiol Spectr; 2024 May; 12(5):e0370323. PubMed ID: 38511952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological Protection 5-6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes.
    Idoko OT; Domingo C; Tapia MD; Sow SO; Geldmacher C; Saathoff E; Kampmann B
    Front Immunol; 2020; 11():577751. PubMed ID: 33133096
    [No Abstract]   [Full Text] [Related]  

  • 18. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.
    Brandriss MW; Schlesinger JJ; Walsh EE; Briselli M
    J Gen Virol; 1986 Feb; 67 ( Pt 2)():229-34. PubMed ID: 3944585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance assessment and validation of a plaque reduction neutralization test (PRNT) in support to yellow fever diagnostic and vaccine clinical trials.
    Dia M; Bob NS; Talla C; Dupressoir A; Escadafal C; Thiam MS; Diallo A; Ndiaye O; Heraud JM; Faye O; Sall AA; Faye O; Fall G
    J Med Virol; 2023 Apr; 95(4):e28700. PubMed ID: 36951314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
    Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.